Related Experiment Video
Updated: Aug 11, 2025
An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment
Published on: July 28, 2012
Lethal activity of BRD4 PROTAC degrader QCA570 against bladder cancer cells
Qiang Wang1,2, Baohu Li2, Wenkai Zhang2
1Department of Urology, Qingdao Municipal Hospital, Qingdao University, Qingdao, China.
Abstract:
Bladder cancer is the most common malignancy of the urinary system. Efforts to identify innovative and effective therapies for bladder cancer are urgently needed. Recent studies have identified the BRD4 protein as the critical factor in regulation of cell proliferation and apoptosis in bladder cancer, and it shows promising potential for pharmacologic treatment against bladder cancer. In this study, we have evaluated the biological function of QCA570, a novel BET degrader, on multiple bladder cancer cells and explore its underlying mechanisms. QCA570 potently induces degradation of BRD4 protein at nanomolar concentrations, with a DC50 of ∼ 1 nM. It decreases EZH2 and c-MYC levels by transcriptional suppression and protein degradation. Moreover, the degrader significantly induces cell apoptosis and cycle arrest and shows antiproliferation activity against bladder cancer cells. These findings support the potential efficacy of QCA570 on bladder cancer.
Insights
A novel BET degrader, QCA570, effectively targets BRD4 protein in bladder cancer cells. This compound shows significant potential for new bladder cancer therapies by inducing apoptosis and inhibiting proliferation.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Bladder cancer is a prevalent urinary system malignancy requiring novel therapeutic strategies.
- The BRD4 protein is identified as a key regulator of cell proliferation and apoptosis in bladder cancer, presenting a promising therapeutic target.
Purpose of the Study:
- To evaluate the biological function and underlying mechanisms of QCA570, a novel BET degrader, in bladder cancer cells.
- To explore the therapeutic potential of QCA570 against bladder cancer.
Main Methods:
- Assessment of QCA570's potency in inducing BRD4 protein degradation.
- Analysis of QCA570's effects on EZH2 and c-MYC protein levels.
- Evaluation of QCA570's impact on bladder cancer cell apoptosis, cell cycle, and proliferation.
Main Results:
- QCA570 potently induced BRD4 protein degradation at nanomolar concentrations (DC50 ≈ 1 nM).
- QCA570 decreased EZH2 and c-MYC levels through transcriptional suppression and protein degradation.
- Significant induction of apoptosis and cell cycle arrest, along with antiproliferative activity, was observed in bladder cancer cells.
Conclusions:
- QCA570 demonstrates potent anti-bladder cancer activity by targeting BRD4.
- The findings support QCA570 as a potential therapeutic agent for bladder cancer treatment.
